Capricor Therapeutics, Inc. (NASDAQ:CAPR - Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $18.77 and traded as low as $5.80. Capricor Therapeutics shares last traded at $6.13, with a volume of 2,748,399 shares changing hands.
Wall Street Analyst Weigh In
Several brokerages have recently commented on CAPR. Piper Sandler raised Capricor Therapeutics from a "neutral" rating to an "overweight" rating in a report on Tuesday, September 1st. Alliance Global Partners cut Capricor Therapeutics from a "buy" rating to a "neutral" rating and set a $7.00 target price on the stock. in a report on Tuesday, July 28th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Capricor Therapeutics in a report on Friday, September 11th. Maxim Group lowered shares of Capricor Therapeutics from a "buy" rating to a "hold" rating in a report on Thursday, July 30th. Finally, Wall Street Zen cut shares of Capricor Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 1st. Four equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $30.25.
View Our Latest Stock Report on CAPR
Capricor Therapeutics Stock Up 4.3%
The firm has a market capitalization of $356.40 million, a P/E ratio of -2.50 and a beta of 0.61. The firm has a 50 day moving average of $8.22 and a 200-day moving average of $18.77.
Capricor Therapeutics (NASDAQ:CAPR - Get Free Report) last issued its quarterly earnings results on Thursday, August 13th. The biotechnology company reported ($0.70) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.11). As a group, research analysts expect that Capricor Therapeutics, Inc. will post -1.71 EPS for the current year.
Hedge Funds Weigh In On Capricor Therapeutics
A number of hedge funds have recently modified their holdings of CAPR. Activest Wealth Management lifted its stake in shares of Capricor Therapeutics by 100.0% in the third quarter. Activest Wealth Management now owns 4,000 shares of the biotechnology company's stock worth $38,000 after acquiring an additional 2,000 shares during the period. KBC Group NV bought a new stake in Capricor Therapeutics in the first quarter worth approximately $44,000. SG Americas Securities LLC acquired a new stake in shares of Capricor Therapeutics during the 1st quarter worth approximately $193,000. Focused Wealth Management Inc bought a new stake in shares of Capricor Therapeutics in the 1st quarter valued at $203,000. Finally, SBI Securities Co. Ltd. boosted its position in shares of Capricor Therapeutics by 834.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 26,310 shares of the biotechnology company's stock worth $249,000 after purchasing an additional 23,495 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company's stock.
About Capricor Therapeutics
(
Get Free Report)
Capricor Therapeutics, Inc is a biotechnology company focused on developing cell and exosome-based therapies for serious diseases. The company's research and development programs are designed to address conditions involving muscle degeneration, inflammation and tissue damage.
Capricor's lead investigational product is deramiocel, also known as CAP-1002, an allogeneic cardiac-derived cell therapy being developed for Duchenne muscular dystrophy. The company has also developed an exosome-based technology platform intended to support the delivery of therapeutic proteins, nucleic acids and other biological materials.
Founded in 2005, Capricor is headquartered in San Diego, California, and conducts its development activities primarily in the United States while working with research, clinical and commercial partners.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Capricor Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Capricor Therapeutics wasn't on the list.
While Capricor Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
